This summary of the update of the guidelines for the management of lower respiratory tract infections and community-acquired pneumonia (CAP) provides an overview on the structure and key points provided in this document. It is based on the structure of the Oxford Centre of Evidence Based Medicine. The update refers to important new insights from studies published by the CAPNETZ and the Bundesgeschäftsstelle für Qualitätssicherung (BQS). Essential new statements as compared to the original 2005 version include the following: 1) treatment of patients with acute exazerbation of COPD (restrictive indications for antimicrobial treatment); 2) preference for the CRB-65 score as tool for the validation of clinical assessment of pneumonia severity; 3) treatment of patients with mild CAP (oral cephalosporins no longer recommended); 4) treatment of patients with moderate CAP (ertapenem as new option in selected cases); 5) treatment of patients with severe CAP (antipseudomonal treatment only rarely indicated; reintroduction of aminoglycosides as agent in combination treatment); 6) reduction of treatment duration; 7) new focus on palliative treatment of patients with CAP.
Definition ! Community-acquired pneumonia is defined as acute infection of lung parenchyma in patients without severe immunosuppression, acquired in the community, excluding those cases with pneumonia within four weeks after hospitalization. Epidemiology ! Data from the mandatory quality improvement program of the "Bundesgeschäftsstelle für Qualitätssicherung (BQS)" indicate that around 200 000 patients are hospitalized with CAP in Germany every year. The overall incidence including outpatients is estimated to reach 400 000 to 600 000 cases per year. Mortality of hospitalized patients is around 13 -14 %, whereas it is very low in ambulatory patients with mild CAP (< 1 %).
Microbial spectrum
! Microbial spectrum of CAP varies considerably according to regional, saisonal, epidemiological und demographic factors. Data collected by CAPNETZ confirm S. pneumoniae as the most important pathogen of CAP [1] (• " Table 1 ). Antimicrobial treatment of patients with CAP is empirical in most instances. Factors such as age, comorbidity, antimicrobial pretreatment etc. are associated with particular pathogens or microbial spectra which should be considered in the selection of adequate empiric initial antimicrobial treatment. CAP through P. aeruginosa requires an antimicrobial treatment most different from any other etiology, however, it was found to be rare in Germany. macrolide resistance is of concern at least in patients with moderate to severe CAP.
Microbial

Microbial investigation !
The amount of microbial investigation required depends on the severity of CAP. Recommendations for empiric initial antimicrobial treatment are based on local and national epidemiology.
Clinical symptoms and findings in lower respiratory tract infection (LRTI)
!
The diagnosis of CAP cannot be firmly made on clinical grounds alone. Chest radiography remains the mainstay to differentiate LRTI and CAP. LRTIs include the following conditions which should be differentiated whenever possible: acute bronchitis, acute exacerbation of COPD, and influenza infection (Recommendation B).
Management of LRTI
!
Patients with acute bronchitis without obstructive lung disease do not require antimicrobial treatment but only symptomatic measures [2] (Recommendations A). Outside a pandemic, clinical diagnosis of influenza infection is not reliable. Antiviral treatment is costly, and excessive prescription represents a key resistance driver. On the other hand, benefits of treatment are limited (reduction of morbidity by around 1.5 days). Therefore, patients with symptoms of saisonal influenza infection should not generally receive antiviral agents. Such treatment may be considered in high risk patients and in those presenting with severe CAP. (Recommendation D). The recommendations for the management of acute exacerbations follow a new approach based primarily on the severity of the acute exacerbation rather than that of COPD since the latter may be difficult to determine confidently at presentation of the patient. Following this structure, patients with severe COPD may present with mild exacerbation as well as the other way round. Indications for antimicrobial treatment are still not clearly established. The key indication for antimicrobial treatment is thought to be an increase of dyspnea and the presence of purulent sputum together with moderate to severe COPD. This view is based on the Stockley criteria rather than the traditional Anthonisen criteria. Thus, in ambulatory patients with mild exacerbations, antimicrobial treatment is recommended only in patients with purulent sputum and (probably) severe COPD. Hospitalized patients should also receive antimicrobial treatment in case of purulent sputum [3] . An alternative approach is based on the determination of procalcitonin (PCT). Patients with PCT < 0,1 ng/ml usually do not require antimicrobial treatment. All patients presenting with severe exacerbations treated at the ICU should receive antimicrobial treatment (Recommendation B). In ambulatory patients with mild exacerbations, first line treatment is an aminopenicillin without betalactamase inhibitor. Alternatives include macrolides and doxycyclin (Recommendation C). In hospitalized patients with moderate to severe exacerbations, an aminopenicillin with betalactamase inhibitor or a parenteral cephalosporin II or III is recommended. Alternatives include respiratory fluoroquinolones (Recommendation C). Patients known to be colonized with P. aeruginosa, with bronchiectasis or requiring ventilatory support should receive an antipseudomonal treatment (acylureidopenicillin plus betalactamase inhibitor, antipseudomonal carbapenem, antipseudomonal cephalosporin or antipseudomonal fluoroquinolone) (Recommendation C). Treatment duration is generally 7 days. Even shorter treatment duration is effective in some indications and antimicrobial agents (macrolides, fluoroquinolones) (Recommendation C).
Acute exacerbation of COPD
Management of CAP
!
Severity stratification of CAP and treatment setting
Risk groups include: 1) mild CAP with or without specific individual risk factors, preferably treated as outpatients; 2) moderate CAP, hospitalized and treated at the regular ward; 3) severe CAP, admitted at the ICU or intermediate care unit.
Hospital admission !
The decision to hospitalize a patient with CAP remains a clinical decision based on severity assessment and other medical and nonmedical considerations. However, CRB-65 should be used as tool to validate pneumonia severity assessment [4, 5] . Hospitalization should be considered in all patients with a CRB-65 score > 0 (• " Table 2 ). Age alone is not an indication to hospitalize. A follow up chest radiography not earlier than 14 days after the end of treatment in order to confirm the diagnosis and exclude malignancy is recommended, particularly in active smokers, elderly patients (> 65 years) and those with severe comorbidity. Table 3 Modified ATS-criteria for severe community-acquired pneumonia. 
Assessment of the following criteria:
respiratory rate ≥ 30/min diastolic blood pressure ≤ 60 mmHg or systolic blood pressure < 90 mmHg pneumonia-associated confusion age ≥ 65 years Management of CAP at the ward ! The clinical relevance of microbial investigation in hospitalized patients with moderate CAP is unsettled. The following investigations are recommended: two sets of blood cultures, diagnostic thoracocentesis and analysis of pleural effusion, L. pneumophilaantigentest in urine as well as sputum in patients with purulent sputum, without antimicrobial pretreatment, provided that the facilities for immediate processing are established (Recommendation B). Recommendations for initial empiric antimicrobial treatment are given in• " Table 6 [6, 7] (Recommendation A). Antimicrobial treatment should initially be administered intravenously. Fluoroquinolones have excellent bioavailability and may be given orally. Macrolides may be given orally as part of a combination treatment with betalactams (Recommendation B). Antimicrobial treatment should be designed as sequential treatment. Oral treatment is possible when clinical stability criteria are met (Recommendation A). Antimicrobial treatment may be stopped 48 -72 h after clinical improvement but not earlier than after 5 days. On the other hand, treatment duration beyond 7 days is usually not required (Recommendation A).
Management of severe CAP (ICU or intermediate care unit)
! Patients with severe CAP are further differentiated in two groups: those with and without risk factors for pneumonia through P. aeruginosa. Pneumonia through P. aeruginosa is rare in Germany. Risk factors include structural lung disease, frequent antimicrobial pretreatment, frequent prior hospitalization (Recommendation C). Microbial investigation should be comprehensive since diagnostic yield and relevance are higher in these patients. The following investigations are recommended: two sets of blood cultures, cultures of sputum or tracheobronchial aspirate, pleural effusion, L. pneumophila-antigentest in urine, bronchoscopy (BAL, PSB).
However, whether etiological diagnosis with or without bronchoscopy has a prognostic impact is unknown (Recommendation B). Inadequate initial antimicrobial treatment and monotherapy may be associated with an excess mortality. Therefore, combination treatment including a broad spectrum betalactam with a non-betalactam is recommended at least in all patients with septic shock (Recommendation B). Recommendations for initial empiric antimicrobial treatment are given in• " Table 7 and• " Table 8 [8] (Recommendation B). Treatment duration should be 8 -10 days or at least 5 days after clinical stability. In CAP through P. aeruginosa, treatment duration should be 8 -15 days (Recommendation B). Table 7 Recommendations for empiric initial antimicrobial treatment in patients with severe CAP without risk factors for P. aeruginosa.
Agents
Daily dosage Treatment duration Treatment of choice** betalactam piperacillin/tazobactam ceftriaxon cefotaxim ertapenem** plus macrolide**** Treatment failure ! Treatment failure is differentiated in two subgroups: primary treatment failure (progressive pneumonia) and slowly responding pneumonia [9] . Progressive pneumonia is defined as clinical deterioration with development of respiratory failure and/or severe sepsis or septic shock despite initial empiric antimicrobial treatment. Slowly responding pneumonia is defined as failure to achieve clinical stability after 72 h of initial empiric antimicrobial treatment and/or failure of radiographic resolution. Aspiration pneumonia ! Aspiration is a risk factor for enterobacteriaceae (GNEB) and probably anaerobes and antimicrobial treatment should cover these pathogens (usually broad spectrum betalactam with betalactamase inhibitor. Alternatives include a combination of a parenteral cephalosporin II or III with clindamycin, moxifloxacin or a carbapenem (Recommendation D).
Lung abscess
! Mixed etiologies including two or more pathogens are frequently present, and also anaerobes are frequently involved. Other etiologies such as fungi (e. g. semi-invasive necrotizing aspergillosis) and Echinococcus spp. have to be taken into account. Bronchoscopy is usually required to confirm pus drainage and exclude potential bronchial obstruction. In addition, a CT-scan is recommended (Recommendation C). Antimicrobial treatment of lung abscess includes an aminopenicillin with betalactamase inhibitor or a parenteral cephalosporin II or III with clindamycin (Recommendation B). Prevention of CAP ! Studies and metaanalyses confirm protection from influenza infection (reduction of influenza associated LRTI and pneumonia, hospitalisation rates and mortality) using influenza vaccine. Absolute risk reduction is two to five times higher in high-risk patients as compared to elderly healthy individuals. In line with the recommendations of STIKO, a yearly vaccination against influenza is recommended in all individuals at increased risk (Recommendation A). Likewise, the body of data indicates that 23-valent capsular pneumococcal polysaccharide vaccine effectively reduces invasive pneumococcal disease. The effect is lower in elderly individuals.
In line with the recommendations of STIKO, pneumococcal polysaccaride vaccination is recommended for all individuals at increased risk for pneumococcal disease (Recommendation A). Cigarette smoking is an important risk factor for CAP. Cessation of cigarette smoking should be propagated (Recommendation A).
CAP as terminal event in elderly and severely disabled patients ! Changes in treatment goals towards palliative treatment may be applied in many ways, e. g. by restriction or limitation of medical interventions and monitoring. Decisions about changes in treatment goals must not follow a hidden agenda but should be discussed, communicated and documented in a transparent way. The indication for palliative treatment is dependent on the will of the patient. Careful exploration of the declared intention, wishes and demands of the patient is mandatory. Patient testimonies may be very helpful to explore the will of a comatose or confused patient; otherwise, the legal social worker has to represent the patient. In critical patients, it may be necessary to assess the indication for palliative treatment repeatedly during treatment. Palliative treatment includes palliative medication, adequate nursing, and personal dedication. The most frequent symptoms which are target for palliative medication include dyspnea, fever, cough, malaise, pain and neuropsychiatric symptoms such as confusion, agitation and anxiety [10] .
